Article
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.
Proceedings of the National Academy of Sciences of the United States of America - 17 Apr 2018
McBrayer Samuel K, Olenchock Benjamin A, DiNatale Gabriel J, Shi Diana D, Khanal Januka, Jennings Rebecca B, Novak Jesse S, Oser Matthew G, Robbins Alissa K, Modiste Rebecca, Bonal Dennis, Moslehi Javid, Bronson Roderick T, Neuberg Donna, Nguyen Quang-De, Signoretti Sabina, Losman Julie-Aurore, Kaelin William G
Abstract excerpt
Inactivation of the retinoblastoma gene (RB1) product, pRB, is common in many human cancers. Targeting downstream effectors of pRB that are central to tumorigenesis is a promising strategy to block the growth of tumors harboring loss-of-function RB1 mutations. One such effector is retinoblastoma-binding protein 2 (RBP2, also called JARID1A or KDM5A), which encodes an H3K4 demethylase. Binding of pRB to RBP2 has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
